Literature DB >> 33425413

Endophthalmitis in Retinopathy of Prematurity after Intravitreal Aflibercept Injection.

Elcin Suren1, Ersan Cetinkaya1, Mustafa Kalayci1, Sariye Elif Özyazıcı Özkan2, Mehmet Fatih Kucuk1, Muhammet Kazim Erol1.   

Abstract

We report the case of a male infant who had an intravitreal anti-VEGF (aflibercept) injection for the treatment of retinopathy of prematurity at 35-week postmenstrual age. Four days following the injection, retinal imaging demonstrated a yellowish gray blurred mass that extended into the vitreous in the right eye, and the vitreous body was blurred. After two days, despite starting endophthalmitis treatment, there was still no improvement in the retinal lesion. Due to the worsening of the clinical signs, we decided to perform 25-gauge lens-sparing pars plana vitrectomy.
Copyright © 2020 Elcin Suren et al.

Entities:  

Year:  2020        PMID: 33425413      PMCID: PMC7772029          DOI: 10.1155/2020/8861435

Source DB:  PubMed          Journal:  Case Rep Ophthalmol Med


  1 in total

1.  The UK practice of Anti-VEGF therapy for treatment of retinopathy of prematurity.

Authors:  Shahanaz B Ahmed; Aisling Higham; Alan Mulvihill; T K J Chan; Gill Adams; Chetan K Patel
Journal:  Eye (Lond)       Date:  2021-04-20       Impact factor: 4.456

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.